Historically, the US, and, in particular, the NASDAQ market, has been the predominant place for IPOs of life sciences and healthcare companies. However, 2018 may be the year in which things start to change....more
3/13/2018
/ Capital Markets ,
CFDA ,
China ,
Health Care Providers ,
Hong Kong ,
Hong Kong Stock Exchange ,
Institutional Investors ,
Life Sciences ,
Listing Rules ,
Listing Standards ,
New Rules ,
NYSE ,
Regulatory Oversight